Startup profile · funding coverage
Gate Bio funding, valuation and investors
Biotech developing oral Molecular Gate medicines that eliminate disease-causing proteins.
Keep track of Gate Bio
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B
$65M · November 2025
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$125M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series b · Brisbane, California
Overview
Gate Bio (also known as Gate Bioscience) develops oral small-molecule drugs using its Molecular Gate platform — a mechanism that blocks secretion of disease-causing proteins rather than inhibiting them inside cells.
Why Gate Bio is interesting
Gate Bio's differentiated protein-secretion blockade attracted ARCH and a16z across a $60M Series A and $65M Series B.
Product & use cases
Gate Bio develops oral molecular gate small molecules that block secretion of disease-causing proteins — distinct from intracellular degraders.
- Inflammatory disease programs toward clinic
- Neurological targets including prion disease
- Lilly partnership for difficult protein targets
Key facts
- Series A (2023): $60M co-led by Versant Ventures and a16z Bio + Health (/fund/andreessen-horowitz) with ARCH Venture Partners (/fund/arch-venture-partners) (BioCentury)
- Series B (2025): $65M with ARCH among existing investors (Gate Bio press)
Funding history (newest first)
Series B
2025-11 $65MSeries A
2023 $60M- Versant Ventures (lead)
- Andreessen Horowitz (lead)
- ARCH Venture Partners (participant)
Source: https://endpoints.news/gate-bioscience-captures-another-65m-with-new-take-on-protein-degradation/
Investors in our directory
Funds linked from Gate Bio's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Secretion-pathway mechanism with oral delivery; repeatable platform across secreted protein targets.
Protein elimination is crowded, but molecular gates target secretory biology. Series B funds IND work through 2028.
-
Arvinas (PROTAC) adjacent
Intracellular degradation; Gate eliminates pre-secretion.
-
Monte Rosa Therapeutics adjacent
Molecular glue degraders — different mechanism.
-
Biologics/antibodies incumbent
Injectable; Gate offers oral alternative.
Notable stories
- Lilly partnership up to $856M for molecular gate targets (Endpoints News, July 2025).
- Total capital raised $135M after Series B (Gate Bio press, Nov 2025).
Industries
Related funding articles
Venture Capital Tracker pieces that cover Gate Bio's financing or category context.
FAQs about Gate Bio
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.